Key facts
- This page summarizes Daniel A. Camardo's Form 4 filing for Cue Biopharma, Inc. (CUE).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 08 Jun 2026, 16:25.
Daniel A. Camardo - 30 May 2026 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)
- Reporting relationship
- Director
- Issuer ticker
- CUE
- Reported as of
- 30 May 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Jun 2026, 16:25:07 UTC
- Prior SEC filing
- 06 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Meluzio, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Daniel A. Camardo filed Form 4 for Cue Biopharma, Inc. (CUE) on 08 Jun 2026.
Change
- Previous filing in this sequence was filed on 06 Oct 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001820365
Primary reporting owner
Camardo Daniel A.
- Relationship
- Director
- Address
- C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON
- Signature
- /s/ Michael Meluzio, Attorney-in-Fact
- Signature date
- 08 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CUE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +1,626
- Change %
- Price
- $0.000000*
- Shares after
- 1,626
- Date
- 30 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,626
- Exercise price
- $21.90
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares underlying the option are scheduled to vest over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly installments.